Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state

References

• Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730–6733.
   PubMed Web of Science ®Google Scholar
• Joshua DE, Brown RD, Ho PJ, et al. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008;8:283–286.
   PubMedGoogle Scholar
• Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701–1711.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329–341.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4 + CD25high FoxP3 + regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940–3949.
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108:804–811.
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301–304.
   PubMed Web of Science ®Google Scholar
• Feyler S, von Lilienfeld-Toal M, Jarmin S, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(−)CD8(−)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009;144:686–695.
   PubMed Web of Science ®Google Scholar
• Gupta R, Ganeshan P, Hakim M, et al. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 2011;35:874–878.
   PubMed Web of Science ®Google Scholar
• Braga WM, Atanackovic D, Colleoni GW. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012;2012:293479.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Neeson P, et al. Regulatory T cells (Treg) are depressed in patients with relapsed/refractory multiple myeloma (MM) and increases towards normal ranges in responding patients treated with lenalidomide (LEN). Blood 2008;112(Suppl. 1): Abstract 1696.
   Google Scholar
• Law JP, Hirschkorn DF, Owen RE, et al. The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+ CD25+ Foxp3 + regulatory T cells. Cytometry A 2009;75:1040–1050.
   PubMed Web of Science ®Google Scholar
• Sattui S, de la Flor C, Sanchez C, et al. Cryopreservation modulates the detection of regulatory T cell markers. Cytometry B Clin Cytom 2012;82:54–58.
   PubMed Web of Science ®Google Scholar
• Minnema MC, van der Veer MS, Aarts T, et al. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+ Foxp3 + T cells. Leukemia 2009;23:605–607.
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012;53:1406–1408.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303–310.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543–9553.
   PubMed Web of Science ®Google Scholar
• Le NT, Chao N. Regulating regulatory T cells. Bone Marrow Transplant 2007;39:1–9.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Manzotti CN, Burke F, et al. Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3. J Immunol 2008; 181:1683–1691.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses?Int Immunol 2009;21: 1105–1111.
   PubMed Web of Science ®Google Scholar
• Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012;7:e35981.
   PubMed Web of Science ®Google Scholar
• Lin YC, Chang LY, Huang CT, et al. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J Immunol 2009;182:6095–6104.
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58: 1033–1045.
   PubMed Web of Science ®Google Scholar
• Shiratori T, Miyatake S, Ohno H, et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 1997;6:583–589.
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Kaur S, Hou TZ, et al. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem 2012;287:9429–9440.
   PubMed Web of Science ®Google Scholar
• Prado C, Gomez J, Lopez P, et al. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity. Immunobiology 2011;216:386–392.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155–167.
   PubMed Web of Science ®Google Scholar
• Xia M, Gasser J, Feige U. Dexamethasone enhances CTLA-4 expression during T cell activation. Cell Mol Life Sci 1999;55: 1649–1656.
   PubMed Web of Science ®Google Scholar
• Jago CB, Yates J, Camara NO, et al. Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol 2004;136: 463–471.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749–760.
   PubMed Web of Science ®Google Scholar
• Menard C, Ghiringhelli F, Roux S, et al. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?Clin Cancer Res 2008;14:5242–5249.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010;37:473–484.
   PubMed Web of Science ®Google Scholar
• Ying H, Yang L, Qiao G, et al. Cutting edge: CTLA-4--B7 interaction suppresses Th17 cell differentiation. J Immunol 2010;185: 1375–1378.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78–88.
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063–6073.
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862–2868.
   PubMed Web of Science ®Google Scholar
• Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011;117:1605–1613.
   PubMed Web of Science ®Google Scholar
• Vieira PL, Christensen JR, Minaee S, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+ CD25+ regulatory T cells. J Immunol 2004;172:5986–5993.
   PubMed Web of Science ®Google Scholar
• Bryant CE, Brown RD, Yang S, et al. Ten year survivors of multiple myeloma demonstrate a differential expression of immunological biomarkers including a high incidence of cytotoxic T-cell clones which have not acquired myeloma-associated anergy. Blood 2011;118(Suppl. 1): Abstract 3924.
   Google Scholar
• Giannopoulos K, Kaminska W, Hus I, et al. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012;106:546–552.
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167–1174.
   PubMed Web of Science ®Google Scholar